Current and Future Prospective of a Versatile Moiety: Imidazole

Nidhi       Rani; Praveen       Kumar; Randhir       Singh; Damião    P.    de Sousa; Prerna       Sharma
Abstract

Imidazole containing compounds have been a very much explored field since ancient times. Subsequently, it constitutes a significant moiety for the new drug development. A variety of compounds having imidazole moiety have been synthesized, evaluated and marketed for the treatment of various diseases such as antifungal, antiepileptic, ACE inhibitors and so on, as shown in the figure. The search for imidazole containing compounds with more selective biological potency with low side effects continues to be an active area of research in medicinal chemistry. This review is in an effort to highlight the marketed drugs with imidazole ring. The article also demonstrates the future prospective of marketed imidazoles as antifungal with potential activity targeting 14α-demethylase enzyme.
Keywords: Azole heterocycle, imidazole, marketed imidazole drug, cytochrome P450, 14α-demethylase, enzyme.
Graphical Abstract

[1] 
Neochoritis C, Tsoleridis CA, Stephanidou-Stephanatou J. Convenient synthesis of polybrominated imidazole building blocks. ARKIVOC  2007; XV: 101-11.
[2] 
Sadjadi S, Heravi MM, Poormohammad N, Oskooie HA, Beheshtiha Y, Bamoharram FF. Direct oxidative conversion of benzoyl chlorides to 2-imidazoles using heteropolyacids. Synth Commun  2009; 39: 3119-25.
[http://dx.doi.org/10.1080/00397910902730978] 
[3] 
Kidwai M, Kukreja S, Rastogi S, Singhal K. Environmentally benign approach to imidazole-2-thiones. Indian J Chem  2007; 46B: 1549-53.
[4] 
Shaabani A, Maleki A, Behnam M. Tandem oxidation process using ceric ammonium nitrate: three-component synthesis of trisubstituted imidazoles under aerobic oxidation conditions. Synth Commun  2009; 39: 102-10.
[http://dx.doi.org/10.1080/00397910802369661] 
[5] 
Boiani M, González M. Imidazole and benzimidazole derivatives as chemotherapeutic agents. Mini Rev Med Chem  2005; 5(4): 409-24.
[http://dx.doi.org/10.2174/1389557053544047] [PMID:  15853629] 
[6] 
Wright SW, Harris RR, Collins RJ, et al. Novel 1-(pyridylphenyl)-1-phenyl-2-imidazolylethanols with topical antiinflammatory activity. J Med Chem  1992; 35(17): 3148-55.
[http://dx.doi.org/10.1021/jm00095a009] [PMID:  1507204] 
[7] 
Grassmann S, Sadek B, Ligneau X, et al. Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H(3)-receptor antagonists. Eur J Pharm Sci  2002; 15(4): 367-78.
[http://dx.doi.org/10.1016/S0928-0987(02)00024-6] [PMID:  11988398] 
[8] 
Soujanya Y, Sastry GN. Theoretical elucidation of the antioxidant mechanism of 1,3-dihydro-1-methyl-2H-imidazole-2-selenol (Msei). Tetrahedron Lett  2007; 48: 2109-12.
[http://dx.doi.org/10.1016/j.tetlet.2007.01.131] 
[9] 
Chen J, Wang Z, Lu Y, Dalton JT, Miller DD, Li W. Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorg Med Chem Lett  2008; 18(11): 3183-7.
[http://dx.doi.org/10.1016/j.bmcl.2008.04.073] [PMID:  18477505] 
[10] 
Das P, Himaja M. Design and synthesis of 4-[2′-(5′-nitro)]imidazolylbenzoyl(N-methyl)aminoacids and peptides. Int. J. Drug Develop. Res  2010; 2(2): 364-70.
[11] 
Ferreira SB, Costa MS, Boechat N, et al. Synthesis and evaluation of new difluoromethyl azoles as antileishmanial agents. Eur J Med Chem  2007; 42(11-12): 1388-95.
[http://dx.doi.org/10.1016/j.ejmech.2007.02.020] [PMID:  17445951] 
[12] 
Valdez CA, Tripp JC, Miyamoto Y, et al. Synthesis and electrochemistry of 2-ethenyl and 2-ethanyl derivatives of 5-nitroimidazole and antimicrobial activity against Giardia lamblia. J Med Chem  2009; 52(13): 4038-53.
[http://dx.doi.org/10.1021/jm900356n] [PMID:  19480409] 
[13] 
Jain R, Vangapandu S, Jain M, Kaur N, Singh S, Singh PP. Antimalarial activities of ring-substituted bioimidazoles. Bioorg Med Chem Lett  2002; 12(13): 1701-4.
[http://dx.doi.org/10.1016/S0960-894X(02)00289-5] [PMID:  12067541] 
[14] 
Brimblecombe RW, Duncan WAM, Durant GJ, Emmett JC, Gannellin CR, Parsons ME. Cimetidine- a new-thiourea H2 receptor antagonist. J Int Med Res  1975; 3: 86-92.
[http://dx.doi.org/10.1177/030006057500300205] 
[15] 
Uçucu O, Karaburun NG, Işikdağ I. Synthesis and analgesic activity of some 1-benzyl-2-substituted-4,5-diphenyl-1H-imidazole derivatives. Farmaco  2001; 56(4): 285-90.
[http://dx.doi.org/10.1016/S0014-827X(01)01076-X] [PMID:  11421256] 
[16] 
Dominianni SJ, Yen TT. Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides. J Med Chem  1989; 32(10): 2301-6.
[http://dx.doi.org/10.1021/jm00130a013] [PMID:  2795602] 
[17] 
Mano T, Stevens RW, Ando K, et al. Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase. Bioorg Med Chem  2003; 11(18): 3879-87.
[http://dx.doi.org/10.1016/S0968-0896(03)00436-X] [PMID:  12927848] 
[18] 
Dyck B, Goodfellow VS, Phillips T, et al. Potent imidazole and triazole CB1 receptor antagonists related to SR141716. Bioorg Med Chem Lett  2004; 14(5): 1151-4.
[http://dx.doi.org/10.1016/j.bmcl.2003.12.068] [PMID:  14980654] 
[19] 
Lange JHM, van der Neut MA, Wals HC, et al. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett  2010; 20(3): 1084-9.
[http://dx.doi.org/10.1016/j.bmcl.2009.12.032] [PMID:  20031412] 
[20] 
Kiselyov AS, Semenova M, Semenov VV, Piatnitski E, Ouyang S. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett  2006; 16(5): 1440-4.
[http://dx.doi.org/10.1016/j.bmcl.2005.11.033] [PMID:  16321531] 
[21] 
Blum CA, Zheng X, De Lombaert S. Design, Synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles:[REMOVED HYPERLINK FIELD] potent and selective neuropeptide Y5-receptor antagonists. J Med Chem  2004; 47: 2318-25.
[http://dx.doi.org/10.1021/jm030490g] [PMID:  15084130] 
[22] 
Nguyen DN, Stump CA, Walsh ES, et al. Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorg Med Chem Lett  2002; 12(9): 1269-73.
[http://dx.doi.org/10.1016/S0960-894X(02)00154-3] [PMID:  11965368] 
[23] 
Sennequier N, Wolan D, Stuehr DJ. Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem  1999; 274(2): 930-8.
[http://dx.doi.org/10.1074/jbc.274.2.930] [PMID:  9873034] 
[24] 
Jackson PF, Bullington JL. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr Top Med Chem  2002; 2(9): 1011-20.
[http://dx.doi.org/10.2174/1568026023393372] [PMID:  12171568] 
[25] 
Wilson KP, McCaffrey PG, Hsiao K, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol  1997; 4(6): 423-31.
[http://dx.doi.org/10.1016/S1074-5521(97)90194-0] [PMID:  9224565] 
[26] 
Bolós J. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. Mini Rev Med Chem  2005; 5(9): 857-68.
[http://dx.doi.org/10.2174/1389557054867048] [PMID:  16178727] 
[27] 
Diller DJ, Lin TH, Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr Top Med Chem  2005; 5(10): 953-65.
[http://dx.doi.org/10.2174/1568026054985948] [PMID:  16178740] 
[28] 
Rani N, Sharma A, Gupta GK, Singh R. Imidazoles as potential antifungal agents: a review. Mini Rev Med Chem  2013; 13(11): 1626-55.
[http://dx.doi.org/10.2174/13895575113139990069] [PMID:  23815583] 
[29] 
Sharma GVM, Jyothi Y, Lakshmi PS. efficient room-temperature synthesis of tri- and tetrasubstituted imidazoles catalyzed by Zrcl4. Synth Commun  2006; 36: 2991-3000.
[http://dx.doi.org/10.1080/00397910600773825] 
[30] 
Rani N, Sharma A, Singh R. Imidazoles as promising scaffolds for antibacterial activity: a review. Mini Rev Med Chem  2013; 13(12): 1812-35.
[http://dx.doi.org/10.2174/13895575113136660091] [PMID:  24032508] 
[31] 
Gupta GK, Rani N, Kumar V. Microwave assisted synthesis of imidazoles: A review. Mini Rev Org Chem  2012; 9: 270-84.
[http://dx.doi.org/10.2174/1570193X11209030270] 
[32] 
Rani N.  synthesis, biological evaluation and computational study of some new imidazole derivatives. m. pharma dissertation, maharishi markandeshwar university, mullana 2011.
[33] 
Rani N, Sharma A, Singh R. Trisubstituted imidazole synthesis: A review. Mini Rev Org Chem  2015; 12(1): 34-65.
[http://dx.doi.org/10.2174/1570193X11666141028235010] 
[34] 
Kathiravan MK, Salake AB, Chothe AS, et al. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem  2012; 20(19): 5678-98.
[http://dx.doi.org/10.1016/j.bmc.2012.04.045] [PMID:  22902032] 
[35] 
Shehabi Y, Botha JA, Ernest D, et al. Clinical application, the use of dexmedetomidine in intensive care sedation. Crit Care Shock  2010; 13: 40-50.
[36] 
Bilehjani E, Kianfar AA, Toofan M, Fakhari S. Anesthesia with etomidate and remifentanil for cesarean section in a patient with severe peripartum cardiomyopathy--a case report. Middle East J Anaesthesiol  2008; 19(5): 1141-9.
[PMID:  18637614] 
[37] 
Block JH, Beale JM. Wilson and Gisvold’s textbook of Organic Medicinal and Pharmaceutical Chemistry.  11th ed.  2004.
[38] 
Annane D. ICU physicians should abandon the use of etomidate! Intensive Care Med  2005; 31(3): 325-6.
[http://dx.doi.org/10.1007/s00134-005-2560-1] [PMID:  15750800] 
[39] 
Lee L. pharmacology - intravenous anesthetic agents & dissociatives veterinary surgery i, vmed 7412 1-14.
[40] 
Crosby TC. metomidate hydrochloride as a sedative for transportation of selected ornamental fishes a thesis presented to the graduate school of the university of florida in partial fulfillment of the requirements for the degree of master of science, university of florida  2008.
[41] 
Olsen Y, Einarsdottir I, Nilssen K. Metomidate anaesthesia in atlantic salmon, salmo salar, prevents plasma cortisol increase during stress. Aquaculture  1995; 134(1-2): 155-68.
[http://dx.doi.org/10.1016/0044-8486(95)00008-P] 
[42] 
Ross R, Backman T, Bennett R. Evaluation of the anesthetic metomidate for the handling and transport of juvenile american shad. Prog Fish-Cult  1993; 55(4): 236-43.
[http://dx.doi.org/10.1577/1548-8640(1993)055<0236:EOTAMF>2.3.CO;2] 
[43] 
Gleadall I. Comparison of anaesthetics for octopuses. Bull Mar Sci  1991; 49(1-2): 663.
[44] 
Sandodden R, Finstad B, Iversen M. Transport stress in atlantic salmon (salmosalar l.): anaesthesia and recovery. Aquacult Res  2001; 32(2): 87-90.
[http://dx.doi.org/10.1046/j.1365-2109.2001.00533.x] 
[45] 
Suwalsky M, Mennickent S, Norris B, Villena F, Cuevas F, Sotomayor CP. The antiepileptic drug diphenylhydantoin affects the structure of the human erythrocyte membrane. Z Natforsch C J Biosci  2004; 59(5-6): 427-31.
[http://dx.doi.org/10.1515/znc-2004-5-625] [PMID:  18998414] 
[46] 
Ali MS, Singh S, Kumar A, Singh S, Ansari MT, Pattnaik G. Preparation and in vitroevaluation of sustained release matrix tablets of phenytoin sodium using natural polymers. Int J Pharm Pharm Sci  2010; 2(3): 174-9.
[47] 
Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev  2012; 64(10): 887-95.
[http://dx.doi.org/10.1016/j.addr.2011.11.006] [PMID:  22210279] 
[48] 
Drug bank http://www.drugbank.ca/drugs/DB007542014
[49] 
Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet  2003; 42(1): 33-58.
[http://dx.doi.org/10.2165/00003088-200342010-00002] [PMID:  12489978] 
[50] 
Yeh JS, Dhir JS, Green AL, Bodiwala D, Brydon HL. Changes in plasma phenytoin level following craniotomy. Br J Neurosurg  2006; 20(6): 403-6.
[http://dx.doi.org/10.1080/02688690601101440] [PMID:  17439093] 
[51] 
Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Kokwaro GO. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. Br J Clin Pharmacol  2002; 54(6): 635-42.
[PMID:  12492612] 
[52] 
Snead C, Siegel N, Hayslett J. Generalized lymphadenopathy and nephrotic syndrome as a manifestation of mephenytoin (mesantoin) toxicity. Pediatrics  1976; 57(1): 98-101.
[PMID:  1246508] 
[53] 
Allen JD, Ekue JM, Shanks RG, Zaidi SA. The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol  1972; 45(4): 561-73.
[http://dx.doi.org/10.1111/j.1476-5381.1972.tb08114.x] [PMID:  5085230] 
[54] 
Dwivedi R, Gogtay N, Kharkar V, Amladi S, Kshirsagar N. In-vitro lymphocyte toxicity to a phenytoin metabolite in phenytoin induced cutaneous adverse drug eruptions. Indian J Dermatol Venereol Leprol  2004; 70(4): 217-20.
[PMID:  17642618] 
[55] 
Mirzai H, Baser EF. Congenital Horner’s syndrome and the usefulness of the apraclonidine test in its diagnosis. Indian J Ophthalmol  2006; 54(3): 197-9.
[http://dx.doi.org/10.4103/0301-4738.27073] [PMID:  16921219] 
[56] 
Searles RV, Shikher V, Balaban CD, Severs WB. Aqueous humor dynamics in anesthetized rats infused with intracameral apraclonidine. Pharmacology  1999; 58(4): 220-6.
[http://dx.doi.org/10.1159/000028284] [PMID:  10077741] 
[57] 
Silvestre JF, Carnero L, Ramón R, Albares MP, Botella R. Allergic contact dermatitis from apraclonidine in eyedrops. Contact Dermat  2001; 45(4): 251.
[http://dx.doi.org/10.1034/j.1600-0536.2001.450421.x] [PMID:  11683848] 
[58] 
Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging  1998; 12(3): 225-41.
[http://dx.doi.org/10.2165/00002512-199812030-00005] [PMID:  9534022] 
[59] 
Meston CM, Gorzalka BB, Wright JM. Inhibition of subjective and physiological sexual arousal in women by clonidine. Psychosom Med  1997; 59(4): 399-407.
[http://dx.doi.org/10.1097/00006842-199707000-00010] [PMID:  9251160] 
[60] 
Basker S, Singh G, Jacob R. Clonidine in paediatrics - a review. Indian J Anaesth  2009; 53(3): 270-80.
[PMID:  20640134] 
[61] 
L’Ami JJ, Vermunt LE, van Loon JP, Sloet van Oldruitenborgh-Oosterbaan MM. Sublingual administration of detomidine in horses: sedative effect, analgesia and detection time. Vet J  2013; 196(2): 253-9.
[http://dx.doi.org/10.1016/j.tvjl.2012.08.016] [PMID:  23062724] 
[62] 
Kariman A, Sharifi D, Nowrouzian I. Evaluation of detomidine hydrochloride, diazepam and thiopental sodium combination on cardiovascular function and hemodynamics in sheep. Small Rumin Res  1998; 29: 43-9.
[http://dx.doi.org/10.1016/S0921-4488(97)00104-1] 
[63] 
Lee D, Yun S, Cho K, Lee H, Choi Y. A case of naphazoline intoxication after the ingestion of a topical antiseptic solution. Hong Kong J Emerg Med  2010; 17(4): 364-6.
[http://dx.doi.org/10.1177/102490791001700409] 
[64] 
Meloun M, Syrový T, Vrána A. The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data. Talanta  2004; 62(3): 511-22.
[http://dx.doi.org/10.1016/j.talanta.2003.08.027] [PMID:  18969326] 
[65] 
Beck-Speier I, Dayal N, Karg E, et al. Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolites. J Pharmacol Exp Ther  2006; 316(2): 843-51.
[http://dx.doi.org/10.1124/jpet.105.093278] [PMID:  16221739] 
[66] 
Ticoll B, Shugar G. Paranoid psychosis induced by oxymetazoline nasal spray. CMAJ  1994; 150(3): 375-6.
[PMID:  8293377] 
[67] 
Khan MA, Khan AA, Faruqi NA. Azelastine and xylometazoline-induced microscopic changes in the nasal mucosa and olfactory bulb. J Anat Soc  2005; 54(2): 18-21.
[68] 
Grigolcit H. Oxymetazoline in allergic rhinitis: a review of controlled clinical trials. J Chin Clin Med  2006; 1(7): 411-7.
[69] 
Spiller HA, Rogers J, Sawyer TS. Drug facilitated sexual assault using an over-the-counter ocular solution containing tetrahydrozoline (Visine). Leg Med (Tokyo)  2007; 9(4): 192-5.
[http://dx.doi.org/10.1016/j.legalmed.2007.01.005] [PMID:  17320456] 
[70] 
Neistadt I. Clinical trial of tetrahydrozoline hydrochloride; a valuable new nasal decongestant. AMA Arch Otolaryngol  1955; 62(2): 143-4.
[http://dx.doi.org/10.1001/archotol.1955.03830020025005] [PMID:  14397923] 
[71] 
Huang M, Ho H, Wen K, Sheu M. High performance liquid chromatography analysis of tetrahydrozoline hydrochloride in ophthalmic solution by silica column eluted with aqueous solvent mixtures. Yao Wu Shi Pin Fen Xi  2002; 10(2): 88-94.
[72] 
Chusid E, Lehr D, Levy W. Severe respiratory depression following nasal instillation of tetrahydrozoline hydrochloride. J Pediatr  1956; 48(1): 66-9.
[http://dx.doi.org/10.1016/S0022-3476(56)80119-4] [PMID:  13295949] 
[73] 
Saper JR, Winner PK, Lake AE III. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache  2001; 41(4): 357-68.
[http://dx.doi.org/10.1046/j.1526-4610.2001.111006357.x] [PMID:  11318882] 
[74] 
freedom of information summary nada, antisedan 2006.
[75] 
Brynne L, Mcnay JL, Schaefer HG, Swedberg K, Wiltse CG, Karlsson MO. Phramacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. Clin Pharmacol  2000; 51: 35-43.
[http://dx.doi.org/10.1046/j.1365-2125.2001.01320.x] 
[76] 
Schachter M. Metabolic effects of moxonidine and other centrally acting antihypertensives. Diabetes Obes Metab  1999; 1(6): 317-22.
[http://dx.doi.org/10.1046/j.1463-1326.1999.00042.x] [PMID:  11225647] 
[77] 
Aarnoudse W, Geven M, Barbato E, Botman KJ, De Bruyne B, Pijls NHJ. Effect of phentolamine on the hyperemic response to adenosine in patients with microvascular disease. Am J Cardiol  2005; 96(12): 1627-30.
[http://dx.doi.org/10.1016/j.amjcard.2005.07.078] [PMID:  16360347] 
[78] 
Rosen RC, Phillips NA, Gendrano NC III, Ferguson DM. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther  1999; 25(2): 137-44.
[http://dx.doi.org/10.1080/00926239908403987] [PMID:  10327383] 
[79] 
Kiel JW, Reitsamer HA. Paradoxical effect of phentolamine on aqueous flow in the rabbit. J Ocul Pharmacol Ther  2007; 23(1): 21-6.
[http://dx.doi.org/10.1089/jop.2006.0102] [PMID:  17341146] 
[80] 
Yasukawa M, Yasukawa K, Kamiizumi Y, Yokoyama R. Intravenous phentolamine infusion alleviates the pain of abdominal visceral cancer, including pancreatic carcinoma. J Anesth  2007; 21(3): 420-3.
[http://dx.doi.org/10.1007/s00540-007-0528-8] [PMID:  17680199] 
[81] 
Bush A, Busst CM, Knight WB, Shinebourne EA. Cardiovascular effects of tolazoline and ranitidine. Arch Dis Child  1987; 62(3): 241-6.
[http://dx.doi.org/10.1136/adc.62.3.241] [PMID:  3566316] 
[82] 
Park KI, Namgung R, Lee C, Han DG. Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease. Yonsei Med J  1990; 31(2): 156-62.
[http://dx.doi.org/10.3349/ymj.1990.31.2.156] [PMID:  2219973] 
[83] 
Csuk R, Woeste B. A chemoenzymatic approach to (+)-pilocarpine. Tetrahedron  2008; 64: 9384-7.
[http://dx.doi.org/10.1016/j.tet.2008.07.100] 
[84] 
 nervous system agents 6th ed. abraham dj. burger’s medicinal chemistry and drug discovery62003 
[85] 
Smith SA, Smith SE, Lazare R. An increased effect of pilocarpine on the pupil by application of the drug in oil. Br J Ophthalmol  1978; 62(5): 314-7.
[http://dx.doi.org/10.1136/bjo.62.5.314] [PMID:  656357] 
[86] 
Navarro Mora G, Bramanti P, Osculati F, et al. Does pilocarpine-induced epilepsy in adult rats require status epilepticus? PLoS One  2009; 4(6)e5759
[http://dx.doi.org/10.1371/journal.pone.0005759] [PMID:  19503612] 
[87] 
Downar E, Waxman MB. Antazoline therapy of recurrent refractory supraventricular arrhythmias--a preliminary report. Can Med Assoc J  1975; 113(5): 391-3.
[PMID:  1098755] 
[88] 
Jantratid E, Prakongpan S, Dressman JB, et al. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. J Pharm Sci  2006; 95(5): 974-84.
[http://dx.doi.org/10.1002/jps.20614] [PMID:  16557528] 
[89] 
Moreno RA, Oliveria C, Brum JL, et al. Cimetidine quantification in human plasma by high performance liquid chromatography coupled to electrospray ionization tandem mass spectrometry. Application to a comapartive pharmacokinetics study. J Bioanal Biomed  2009; 1(1): 5-13.
[90] 
Barbezat GO, Grant B, Bank S, Vinik A. The effect of histamine H2-receptor blockade with metiamide on serum gastrin levels in man. Gut  1975; 16(3): 186-7.
[http://dx.doi.org/10.1136/gut.16.3.186] [PMID:  1123173] 
[91] 
Bird TL, Larkin MM, Betton GR. Toxic effects of the histamine H(2) receptor antagonist metiamide on bone-marrow haemopoietic and stromal progenitor cells in vitro. Toxicol In Vitro  1988; 2(3): 221-4.
[http://dx.doi.org/10.1016/0887-2333(88)90011-2] [PMID:  20702338] 
[92] 
Blankestijn PJ, Rupp H. Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem  2008; 6(4): 253-7.
[http://dx.doi.org/10.2174/187152508785909500] [PMID:  18855637] 
[93] 
Schrader J, Lüders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke  2005; 36(6): 1218-26.
[http://dx.doi.org/10.1161/01.STR.0000166048.35740.a9] [PMID:  15879332] 
[94] 
Ers HN, Gogas-Yayuz D, Zdouan O, Budak Y, Akalyn S. The effect of losartan on plasma atrial natriuretic peptide levels in the diabetic. rat model. Turkish. J Endocrinol Metab  1999; 1: 17-22.
[95] 
Rout PK, Nayak BS, Nayak UK. The effect of losartan on plasma atrial natriuretic peptide levels in the diabetic. rat model Turkish. J Endocrinol Metab  2009; 1: 17-22.
[96] 
Norwood D, Branch E, Smith B, Honeywell M. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast  2002; 27(12): 611-8.
[97] 
Aletrari M, Kanari P, Partassides D, Loizou E. Study of the British Pharmacopeia method on methimazole (thiamazole) content in carbimazole tablets. J Pharm Biomed Anal  1998; 16(5): 785-92.
[http://dx.doi.org/10.1016/S0731-7085(97)00119-2] [PMID:  9535190] 
[98] 
Economou A, Tzanavaras PD, Notou M, Themelis DG. Determination of methimazole and carbimazole by flow-injection with chemiluminescence detection based on the inhibition of the Cu(II)-catalysed luminol–hydrogen peroxide reaction. Anal Chim Acta  2004; 505: 129-33.
[http://dx.doi.org/10.1016/S0003-2670(03)00176-4] 
[99] 
Khan ZK, Jain P. Antifungal agents and immunomodulators in systemic mycoses. Indian J Chest Dis Allied Sci  2000; 42(4): 345-55.
[PMID:  15597684] 
[100] 
Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health--chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther  2003; 26(1): 5-29.
[http://dx.doi.org/10.1046/j.1365-2885.2003.00456.x] [PMID:  12603774] 
[101] 
Marriott MS. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J Gen Microbiol  1980; 117(1): 253-5.
[PMID:  6993625] 
[102] 
Lackner TE, Clissold SP. Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs  1989; 38(2): 204-25.
[http://dx.doi.org/10.2165/00003495-198938020-00004] [PMID:  2670516] 
[103] 
Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev  1988; 1(2): 187-217.
[http://dx.doi.org/10.1128/CMR.1.2.187] [PMID:  3069196] 
[104] 
Menozzi G, Merello L, Fossa P, et al. Synthesis, antimicrobial activity and molecular modeling studies of halogenated 4-[1H-imidazol-1-yl(phenyl)methyl]-1,5-diphenyl-1H-pyrazoles. Bioorg Med Chem  2004; 12(20): 5465-83.
[http://dx.doi.org/10.1016/j.bmc.2004.07.029] [PMID:  15388173] 
[105] 
Rotstein DM, Walker KAM. The synthesis and antifungal activity of the enantiomers of butaconazole nitrate. Tetrahedron:Assym  1993; 4(7): 1521-6.
[http://dx.doi.org/10.1016/S0957-4166(00)80353-5] 
[106] 
Kidwai M, Venkataramanan R, Rastogi S, Sapra P. Discovery and development of antifungal compounds. Curr Med Chem  2003; 2: 27-71.
[107] 
Couteau C, Jaduad M, Peigne F, Coiffard LJM. Influence of pH on the photodegradation kinetics under UV light of climbazole solutions. Analusis  2000; 28: 557-60.
[http://dx.doi.org/10.1051/analusis:2000171] 
[108] 
Yang W, Li J, Chen Q, Yang G. Novel synthetic methods for N-cyano-1H-imidazole-4-carboxamides and their fungicidal activity. Bioorg Med Chem Lett 2011.
[http://dx.doi.org/10.1016/j.bmcl.2011.11.115] [PMID:  22189134] 
[109] 
Abu-Jdayil B, Mohameed HA. Rheology of Dead Sea shampoo containing the antidandruff climbazole. Int J Cosmet Sci  2004; 26(6): 281-9.
[http://dx.doi.org/10.1111/j.1467-2494.2004.00240.x] [PMID:  18492152] 
[110] 
Vanitha J, Kumar AS, Ganesh M, Sarvanan VS. Comaparative analysis of climbazole in pharmaceutical formulation. Asian J Res Chem  2008; 1(1): 43-5.
[111] 
Lefler E, Stevens DA. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother  1984; 25(4): 450-4.
[http://dx.doi.org/10.1128/AAC.25.4.450] [PMID:  6375555] 
[112] 
Beierdörffer H, Michel G, Kehr K. Croconazole in the treatment of tinea pedis. Mycoses  1995; 38(11-12): 501-7.
[http://dx.doi.org/10.1111/j.1439-0507.1995.tb00028.x] [PMID:  8720204] 
[113] 
Barbanoj MJ, Antonijoan R, García-Gea C, Puntes M, Gich I, Jané F. Eberconazole cream: topical and general tolerability, sensitisation potential, and systemic availability. Methods Find Exp Clin Pharmacol  2005; 27(4): 227-34.
[http://dx.doi.org/10.1358/mf.2005.27.4.893581] [PMID:  16082423] 
[114] 
Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR. Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream. Int J Dermatol  2006; 45(5): 600-4.
[http://dx.doi.org/10.1111/j.1365-4632.2006.02841.x] [PMID:  16700802] 
[115] 
Torres-Rodríguez JM, Mendez R, López-Jodra O, et al. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Antimicrob Agents Chemother  1999; 43(5): 1258-9.
[http://dx.doi.org/10.1128/AAC.43.5.1258] [PMID:  10223946] 
[116] 
Heel RC, Brogden RN, Speight TM, Avery GS. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs  1978; 16(3): 177-201.
[http://dx.doi.org/10.2165/00003495-197816030-00001] [PMID:  98315] 
[117] 
Hnilica KA, Medleau L. Evaluation of topically applied enilconazole for the treatment of dermatophytosis in a Persian cattery. Vet Dermatol  2002; 13(1): 23-8.
[http://dx.doi.org/10.1046/j.0959-4493.2001.00282.x] [PMID:  11896967] 
[118] 
Jones BM, Geary I, Lee ME, Duerden BI. Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother  1989; 33(6): 970-2.
[http://dx.doi.org/10.1128/AAC.33.6.970] [PMID:  2764547] 
[119] 
Veraldi S, Milani R. Topical fenticonazole in dermatology and gynaecology: current role in therapy. Drugs  2008; 68(15): 2183-94.
[http://dx.doi.org/10.2165/00003495-200868150-00007] [PMID:  18840006] 
[120] 
Pfaller MA. A clinical review of antibacterial, antifungal and antiviral drugs Kucers! the use of antibiotics 6th ed.  2010.
[121] 
del Palacio Cuétara S.  izquierdo i, et al A double-blind, randomized comparative trial: flutrimazole 1% solution versus bifonazole 1% solution once daily in dermatomycoses. Mycoses  1995; 38(9-10): 395-403.
[http://dx.doi.org/10.1111/j.1439-0507.1995.tb00071.x] [PMID:  8569816] 
[122] 
Rigopoulos D, Gregoriou S, Kontochristopoulos G, Ifantides A, Katsambas A. Flutrimazole shampoo 1% versus ketoconazole shampoo 2% in the treatment of pityriasis versicolor. A randomised double-blind comparative trial. Mycoses  2007; 50(3): 193-5.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01352.x] [PMID:  17472615] 
[123] 
Dhawale SC, Ranpise HA, Sanap DK, Mathure DM, Ranpise AA. Formulation development and in vitro evaluation of PLGA nanoparticles of flutrimazole. Int J Univ Pharm Bio Sci  2013; 2(5): 310-26.
[124] 
Cohen L. Single dose treatment of vaginal candidosis: comparison of clotrimazole and isoconazole. Br J Vener Dis  1984; 60(1): 42-4.
[http://dx.doi.org/10.1136/sti.60.1.42] [PMID:  6365236] 
[125] 
Agah S, Fereshtehnejad S, Yousefnejad A, Siavashi F. Antimicrobial activity of ketoconazole and fluconazole against metronidazole resistance strains of Helicobacter pylori. Int J Pharm Tech  2008; 7: 57-60.
[126] 
Leun CY. Antifungal therapy in dermatology. J Hong Kong Med Assoc  1990; 42(4): 203-5.
[127] 
Furukawa K, Sasaki H, Pollard RB, Suzuki F. Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. J Antimicrob Chemother  2000; 46(3): 443-50.
[http://dx.doi.org/10.1093/jac/46.3.443] [PMID:  10980172] 
[128] 
Niwano Y, Ohmi T, Seo A, Kodama H, Koga H, Sakai A. Lanoconazole and its related optically active compound nnd-502:novel antifungal imidazoles with a ketene dithioacetal structure. Curr Med Anti Infect Agents  2003; 2: 147-60.
[http://dx.doi.org/10.2174/1568012033483097] 
[129] 
Niwano Y, Tabuchi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent. Antimicrob Agents Chemother  1995; 39(10): 2353-5.
[http://dx.doi.org/10.1128/AAC.39.10.2353] [PMID:  8619597] 
[130] 
Tanaka T, Satoh T, Yokozeki H. Allergic contact dermatitis from luliconazole: implication of the dithioacetal structure  2006; 271-2.
[131] 
Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis--comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses  2007; 50(1): 35-40.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01305.x] [PMID:  17302746] 
[132] 
Watanabe S, Takahashi H, Nishikawa T, et al. A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses  2006; 49(3): 236-41.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01218.x] [PMID:  16681817] 
[133] 
Shono M. Allergic contact dermatitis from luliconazole. Contact Dermat  2007; 56(5): 296-7.
[http://dx.doi.org/10.1111/j.1600-0536.2006.01023.x] [PMID:  17441865] 
[134] 
Kazy Z, Puhó E, Czeizel AE. The possible association between the combination of vaginal metronidazole and miconazole treatment and poly-syndactyly Population-based case-control teratologic study. Reprod Toxicol  2005; 20(1): 89-94.
[http://dx.doi.org/10.1016/j.reprotox.2004.11.012] [PMID:  15808791] 
[135] 
Tatsumi Y, Yokoo M, Arika T, Yamaguchi H. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother  2001; 45(5): 1493-9.
[http://dx.doi.org/10.1128/AAC.45.5.1493-1499.2001] [PMID:  11302816] 
[136] 
Ogura H, Kobayashi H, Nagai K, et al. Synthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agents. Chem Pharm Bull (Tokyo)  1999; 47(10): 1417-25.
[http://dx.doi.org/10.1248/cpb.47.1417] [PMID:  10553638] 
[137] 
Uchida K, Itoyama T, Yamaguchi H.  [in vitro antifungal activity of omoconazole nitrate, a novel imidazone antimycotic drug, against clinical isolates from patients with cutaneous mycosis]. Jpn J Antibiot  1996; 49(8): 818-23.
[PMID:  9053537] 
[138] 
Itoyama T, Uchida K, Yamaguchi H, Fujita S. Therapeutic effects of omoconazole nitrate on experimental tinea pedis, an intractable dermatophytosis, in guinea-pigs. J Antimicrob Chemother  1997; 40(3): 441-4.
[http://dx.doi.org/10.1093/jac/40.3.441] [PMID:  9338501] 
[139] 
Rossello A, Bertini S, Lapucci A, et al. Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem  2002; 45(22): 4903-12.
[http://dx.doi.org/10.1021/jm020980t] [PMID:  12383016] 
[140] 
Wistreich GA. candidiasis and cryptococcosis: two costly healthcare burdens rc educational consultingservices, inc 
[141] 
Chitescu CL, Nicolau A. Another point of view on side effects of antifungal compounds used in veterinary medicine. Vet Drug  2011; 5(1): 68-74.
[142] 
Ford MM. Antifungals and their use in veterinary ophthalmology. Vet Clin North Am Small Anim Pract  2004; 34(3): 669-91.
[http://dx.doi.org/10.1016/j.cvsm.2003.12.002] [PMID:  15110978] 
[143] 
Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs  2009; 69(3): 339-59.
[http://dx.doi.org/10.2165/00003495-200969030-00009] [PMID:  19275277] 
[144] 
Benfield P, Clissold SP. Sulconazole: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs  2009; 69(3): 339-59.
[PMID:  19275277] 
[145] 
Clissold SP, Heel RC. Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs  1986; 31(1): 29-51.
[http://dx.doi.org/10.2165/00003495-198631010-00003] [PMID:  3510114] 
[146] 
Ganjali MR, Norouzi P, Faridbod F, Pirelahi H. Novel metronidazole membrane sensor based on a 2,6-(p-N,N-dimethylaminophenyl)-4-phenylthiopyrylium perchlorate. J Chin Chem Soc (Taipei)  2007; 54: 55-61.
[http://dx.doi.org/10.1002/jccs.200700010] 
[147] 
Singh PP, Jain H. Trichomoniasis: chemotherapy, drug-resistance and new targets. J Parasit Dis  2007; 31(2): 79-91.
[148] 
Cantelli-Forti G, Paolini M, Hrelia P, Sapigni E, Biagi GL. Effects of metronidazole, azanidazole, and azathioprine on cytochrome P450 and various mono-oxygenase activities in hepatic microsomes from control and induced mice. Arch Toxicol Suppl  1987; 11: 264-9.
[http://dx.doi.org/10.1007/978-3-642-72558-6_48] [PMID:  3477179] 
[149] 
Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother  2009; 64(6): 1139-47.
[http://dx.doi.org/10.1093/jac/dkp357] [PMID:  19819909] 
[150] 
Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas’ disease in adults. Antimicrob Agents Chemother  2010; 54(11): 4896-9.
[http://dx.doi.org/10.1128/AAC.00537-10] [PMID:  20823286] 
[151] 
Notowicz A, Stolz E, de Koning GA. First experiences with single-dose treatment of vaginal trichomoniasis with carnidazole (R 25831). Br J Vener Dis  1977; 53(2): 129-31.
[http://dx.doi.org/10.1136/sti.53.2.129] [PMID:  322823] 
[152] 
Fernie DS, Ware DA, Park RW. The effect of the nitroimidazole drug dimetridazole on microaerophilic campylobacters. J Med Microbiol  1977; 10(2): 233-40.
[http://dx.doi.org/10.1099/00222615-10-2-233] [PMID:  558335] 
[153] 
Tweit RC, Kreider EM, Muir RD. Synthesis of antimicrobial nitroimidazolyl 2-sulfides, -sulfoxides, and -sulfones. J Med Chem  1973; 16(10): 1161-9.
[http://dx.doi.org/10.1021/jm00268a021] [PMID:  4201423] 
[154] 
Moeller MW. Effect of dimetridazole on rate of gain and feed efficiency in swine. J Anim Sci  1967; 26(1): 64-6.
[http://dx.doi.org/10.2527/jas1967.26164x] [PMID:  6031645] 
[155] 
Ho C, Sin DWM, Wong KM, Tang HPO. Determination of dimetridazole and metronidazole in poultry and porcine tissues by gas chromatography–electron capture negative ionization mass spectrometry. Anal Chim Acta  2005; 530: 23-31.
[http://dx.doi.org/10.1016/j.aca.2004.09.004] 
[156] 
Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res  2002; 511(2): 133-44.
[http://dx.doi.org/10.1016/S1383-5742(02)00007-8] [PMID:  12052431] 
[157] 
El-Kamel AH, Ashri LY, Alsarra IA. Micromatricial metronidazole benzoate film as a local mucoadhesive delivery system for treatment of periodontal diseases. AAPS PharmSciTech  2007; 8(3)E75
[http://dx.doi.org/10.1208/pt0803075] [PMID:  17915825] 
[158] 
Overgaard J, Eriksen JG, Nordsmark M. ALsner, J.; Horsman, M.R. Plasma Osteopontin, hypoxia, and response to the hypoxia sensitizer nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA5 randomised double blind placebo-controlled trial. Lancet Oncol  2005; 6: 757-64.
[http://dx.doi.org/10.1016/S1470-2045(05)70292-8] [PMID:  16198981] 
[159] 
Reynolds AV, Hamilton-Miller JMT, Brumfitt W. A comparison of the in vitro activity of metronidazole, tinidazole, and nimorazole against Gram-negative anaerobic bacilli. J Clin Pathol  1975; 28(10): 775-8.
[http://dx.doi.org/10.1136/jcp.28.10.775] [PMID:  1214009] 
[160] 
Solbach W, Wagner H, Röllinghoff M. Effect of niridazole in cellular immunity in vivo and in vitro. Clin Exp Immunol  1978; 32(3): 411-8.
[PMID:  357051] 
[161] 
Rudofsky UH, Pollara B. Studies on the pathogenesis of experimental autoimmune renal tubulointerstitial disease in guinea-pigs. IV. failure to inhibit mononuclear cell accumulation with niridazole. Clin Exp Immunol  1977; 27(3): 522-5.
[PMID:  862238] 
[162] 
Barat R, Srinatha A, Pandit JK, Mittal N, Anupurba S. Ethylcellulose inserts of an orphan drug for periodontitis: preparation, in vitro, and clinical studies. Drug Deliv  2007; 14(8): 531-8.
[http://dx.doi.org/10.1080/10717540701606517] [PMID:  18027183] 
[163] 
Simen YH, Zeynep AY, Mine O. Bioavailability file: ornidazole. FABAD J Pharm Sci  2004; 29: 133-44.
[164] 
Gookin JL, Copple CN, Papich MG, et al. Efficacy of ronidazole for treatment of feline Tritrichomonas foetus infection. J Vet Intern Med  2006; 20(3): 536-43.
[http://dx.doi.org/10.1111/j.1939-1676.2006.tb02893.x] [PMID:  16734086] 
[165] 
Davidson GS. Ronidazole in the treatment of trichomonad infections in cats. Int J Pharm Compd  2006; 10(6): 434-5.
[PMID:  23974416] 
[166] 
Sams MJ, Strutt PR, Barnes KA, Damant AP, Rose MD. Determination of dimetridazole, ronidazole and their common metabolite in poultry muscle and eggs by high performance liquid chromatography with UV detection and confirmatory analysis by atmospheric pressure chemical ionisation mass spectrometry. Analyst (Lond)  1998; 123(12): 2545-9.
[http://dx.doi.org/10.1039/a805204b] [PMID:  10435296] 
[167] 
Rosenblum C, Trenner NR, Buhs RP, Hiremath CB, Koniuszy FR, Wolf DE. Metabolism of ronidazole (1-methyl-5-nitroimidazol-2-ylmethyl carbamate). J Agric Food Chem  1972; 20(2): 360-71.
[http://dx.doi.org/10.1021/jf60180a053] [PMID:  5016619] 
[168] 
Agrahari V, Bajpai M, Nanda S. Development of simple UV-spectrometric assay method for satranidazole and study of its degradation profile. Int Res J Pharm  2013; 4(4): 209-13.
[http://dx.doi.org/10.7897/2230-8407.04442] 
[169] 
Bansal K, Rawat MK, Jain A, Rajput A, Chaturvedi TP, Singh S. Development of satranidazole mucoadhesive gel for the treatment of periodontitis. AAPS PharmSciTech  2009; 10(3): 716-23.
[http://dx.doi.org/10.1208/s12249-009-9260-z] [PMID:  19479385] 
[170] 
Ptel MB, Patel KM, Patel GS. Development and validation of a stability-indicating hptlc-densitometric method for satranidazole. J Liq Chromatogr Relat Technol  2007; 30: 2459-71.
[http://dx.doi.org/10.1080/10826070701465852] 
[171] 
Kumar P, Rao PYV, Kumar BK, Prasanthi V, Murty BS. Direct spectrometric determination of satranidazole. Int J Pharm Sci Res  2012; 3(9): 3314-6.
[172] 
Jiménez JC, Rodríguez N, Di Prisco MC, Lynch NR, Costa V. Haemoglobin concentrations and infection by Giardia intestinalis in children: effect of treatment with secnidazole. Ann Trop Med Parasitol  1999; 93(8): 823-7.
[http://dx.doi.org/10.1080/00034983.1999.11813489] [PMID:  10715676] 
[173] 
Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol  2010; 2010: 1-6.
[http://dx.doi.org/10.1155/2010/705692] [PMID:  20885970] 
[174] 
Girginkardeşler N, Coşkun S, Cüneyt Balcioğlu I, Ertan P, Ok UZ. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin Microbiol Infect  2003; 9(2): 110-3.
[http://dx.doi.org/10.1046/j.1469-0691.2003.00504.x] [PMID:  12588330] 
[175] 
Upcroft JA, Dunn LA, Wright JM, Benakli K, Upcroft P, Vanelle P. 5-Nitroimidazole drugs effective against metronidazole-resistant Trichomonas vaginalis and Giardia duodenalis. Antimicrob Agents Chemother  2006; 50(1): 344-7.
[http://dx.doi.org/10.1128/AAC.50.1.344-347.2006] [PMID:  16377707] 
[176] 
Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother  2006; 50(12): 4209-10.
[http://dx.doi.org/10.1128/AAC.00814-06] [PMID:  17000740] 
[177] 
Ouyang LQ, Wu HL, Liu YJ, et al. Simultaneous determination of metronidazole and tinidazole in plasma by using hplc-dad coupled with second-order calibration. Chin Chem Lett  2010; 21: 1223-6.
[http://dx.doi.org/10.1016/j.cclet.2010.04.016] 
[178] 
Singbal SS, Rataboli PV. Anaphylaxis and hypersensitivity syndrome reactions in increasing severity following repeated exposure to tinidazole. J Postgrad Med  2005; 51(3): 243-4.
[PMID:  16333209] 
[179] 
Brumfitt W, Hamilton-Miller JMT, Gooding A. Importance of methodology in determining bactericidal and bacteriostatic activities of azlocillin and ticarcillin against Pseudomonas aeruginosa. J Med Microbiol  1984; 17(1): 37-44.
[http://dx.doi.org/10.1099/00222615-17-1-37] [PMID:  6420572] 
[180] 
Leung ACT, Orange G, Henderson LS, Sleigh JD. Successful use of combined intraperitoneal azlocillin and aminogl ycoside in the treatment of dialysis associated Pseudomonas peritonitis. Perit Dial Int  1984; 4(2): 98-102.
[http://dx.doi.org/10.1177/089686088400400212] 
[181] 
Fu KP, Neu HC. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother  1978; 13(6): 930-8.
[http://dx.doi.org/10.1128/AAC.13.6.930] [PMID:  677860] 
[182] 
Pryka RD. An evaluation of the safety and efficacy of aztreonam versus azlocillin plus tobramycin in the treatment of pulmonary exacerbations in cystic fibrosis patients phd dissertation, university of utah 1987.
[183] 
Frimodt-Möller N, Maigaard S, Toothaker RD, et al. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function. Antimicrob Agents Chemother  1980; 17(4): 599-607.
[http://dx.doi.org/10.1128/AAC.17.4.599] [PMID:  6446877] 
[184] 
Issell BF, Bodey GP, Weaver S. Clinical pharmacology of mezlocillin. Antimicrob Agents Chemother  1978; 13(2): 180-3.
[http://dx.doi.org/10.1128/AAC.13.2.180] [PMID:  646340] 
[185] 
Wang Y, Gray JP, Mishin V, Heck DE, Laskin DL, Laskin JD. Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med  2008; 44(6): 1169-79.
[http://dx.doi.org/10.1016/j.freeradbiomed.2007.12.013] [PMID:  18206659] 
[186] 
Wasserman BN, Chronister TE, Stark BI, Saran BR. Ocular myasthenia and nitrofurantoin. Am J Ophthalmol  2000; 130(4): 531-3.
[http://dx.doi.org/10.1016/S0002-9394(00)00556-0] [PMID:  11024434] 
[187] 
Balfour JAB, Figgitt DP. Telithromycin. Drugs  2001; 61(6): 815-29.
[http://dx.doi.org/10.2165/00003495-200161060-00016] [PMID:  11398913] 
[188] 
Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut  2002; 50(4): 485-9.
[http://dx.doi.org/10.1136/gut.50.4.485] [PMID:  11889067] 
[189] 
Kasper M, Barth K. Bleomycin and its role in inducing apoptosis and senescence in lung cells - modulating effects of caveolin-1. Curr Cancer Drug Targets  2009; 9(3): 341-53.
[http://dx.doi.org/10.2174/156800909788166501] [PMID:  19442053] 
[190] 
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol  2003; 14(1): 91-6.
[http://dx.doi.org/10.1093/annonc/mdg020] [PMID:  12488299] 
[191] 
Sanada M, Takagi Y, Ito R, Sekiguchi M. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair (Amst)  2004; 3(4): 413-20.
[http://dx.doi.org/10.1016/j.dnarep.2003.12.008] [PMID:  15010317] 
[192] 
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med  2011; 364(26): 2517-26.
[http://dx.doi.org/10.1056/NEJMoa1104621] [PMID:  21639810] 
[193] 
Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology  2001; 58(6): 1016-20.
[http://dx.doi.org/10.1016/S0090-4295(01)01455-8] [PMID:  11744479] 
[194] 
Ask K, Décologne N, Asare N, et al. Distribution of nitroreductive activity toward nilutamide in rat. Toxicol Appl Pharmacol  2004; 201(1): 1-9.
[http://dx.doi.org/10.1016/j.taap.2004.04.006] [PMID:  15519603] 
[195] 
Yamazaki Y, Tanaka K, Nicholson B, et al. Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure. J Med Chem  2012; 55(3): 1056-71.
[http://dx.doi.org/10.1021/jm2009088] [PMID:  22185476] 
[196] 
Li Y, Wang S, Li Z. Design, synthesis, and insecticidal activity of novel neonicotinoid derivatives containing n-oxalyl groups. ARKIVOC  2009; XI: 152-64.
[197] 
Bhardwaj S, Srivastava MK, Kapoor U, Srivastava LPAA. 90 days oral toxicity of imidacloprid in female rats: morphological, biochemical and histopathological evaluations. Food Chem Toxicol  2010; 48(5): 1185-90.
[http://dx.doi.org/10.1016/j.fct.2010.02.009] [PMID:  20146932] 
[198] 
Mizushina Y, Matsukage A, Sakaguchi K. The biochemical inhibition mode of bredinin-5′-monophosphate on DNA polymerase β. Biochim Biophys Acta  1998; 1403(1): 5-11.
[http://dx.doi.org/10.1016/S0167-4889(98)00027-5] [PMID:  9622583] 
[199] 
Sakaguchi K, Tsujino M, Yoshizawa M, Mizuno K, Hayano K. Action of bredinin on mammalian cells. Cancer Res  1975; 35(7): 1643-8.
[PMID:  1055633] 
[200] 
Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics. Pharmaceuticals (Basel)  2012; 5(8): 802-36.
[http://dx.doi.org/10.3390/ph5080802] [PMID:  24280676] 
[201] 
Srivastava PC, Streeter DG, Matthews TR, Allen LB, Sidwell RW, Robins RK. Synthesis and antiviral and antimicrobial activity of certain 1-β-D-ribofuranosyl-4,5-disubstituted imidazoles. J Med Chem  1976; 19(8): 1020-6.
[http://dx.doi.org/10.1021/jm00230a009] [PMID:  184281] 
[202] 
Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol 2009.2009681482
[http://dx.doi.org/10.1155/2009/681482] [PMID:  20052390] 
[203] 
Humble RW, Middleton DF, Banoub J, Ewing DF, Boa AN, Mackenzie G. A synthesis of bredinin (Mizoribine) from an acyclic precursor. Tetrahedron Lett  2011; 52: 6223-7.
[http://dx.doi.org/10.1016/j.tetlet.2011.09.085] 
[204] 
Ochiai C, Asano T, Takakura K, Fukuda T, Horizoe H, Morimoto Y. Mechanisms of cerebral protection by pentobarbital and nizofenone correlated with the course of local cerebral blood flow changes. Stroke  1982; 13(6): 788-96.
[http://dx.doi.org/10.1161/01.STR.13.6.788] [PMID:  7147293] 
[205] 
Hussain T, Siddiqui HL. Zia-ur-Rehman M, Masoom Yasinzai M, Parvez M. Anti-oxidant, anti-fungal and anti-leishmanial activities of novel 3-[4-(1H-imidazol-1-yl) phenyl]prop-2-en-1-ones. Eur J Med Chem  2009; 44(11): 4654-60.
[http://dx.doi.org/10.1016/j.ejmech.2009.06.038] [PMID:  19664864] 
[206] 
Liu Y, Zhuang X, Gou L, et al. Protective effects of nizofenone administration on the cognitive impairments induced by chronic restraint stress in mice. Pharmacol Biochem Behav  2013; 103(3): 474-80.
[http://dx.doi.org/10.1016/j.pbb.2012.09.009] [PMID:  23026061] 
[207] 
Shoham S, Groll AH, Petraitis V, Walsh TJ. systemic antifungal agents infectious diseases 4th 2017; 2: 1333-44.
[http://dx.doi.org/10.1016/b978-0-7020-6285-8.00156-8] 
[208] 
Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem  2006; 49(11): 3315-21.
[http://dx.doi.org/10.1021/jm051197e] [PMID:  16722650] 
[209] 
Cupp-Vickery JR, Garcia C, Hofacre A, McGee-Estrada K. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. J Mol Biol  2001; 311(1): 101-10.
[http://dx.doi.org/10.1006/jmbi.2001.4803] [PMID:  11469860] 
[210] 
Ji H, Zhang W, Zhou Y, et al. A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem  2000; 43(13): 2493-505.
[http://dx.doi.org/10.1021/jm990589g] [PMID:  10891108] 
Cite As
Current Drug Targets

Current and Future Prospective of a Versatile Moiety: Imidazole

Abstract

Graphical Abstract
